Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 577Triple Negative Breast Neoplasms 125Neoplasm Metastasis 50Breast Neoplasms, Male 28Ovarian Neoplasms 26Neoplasms 26Inflammatory Breast Neoplasms 22Carcinoma, Non-Small-Cell Lung 19Stomach Neoplasms 14Endometrial Neoplasms 11Carcinoma, Ductal, Breast 11Carcinoma, Ovarian Epithelial 10Pancreatic Neoplasms 9Colorectal Neoplasms 9Melanoma 8Lung Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7HER2-positive Breast Cancer 7Squamous Cell Carcinoma of Head and Neck 6Prostatic Neoplasms 6Esophageal Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 4Brain Neoplasms 4Anatomic Stage I Breast Cancer AJCC v8 4Advanced Breast Cancer 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3

Interventions

eribulin 1disitamab vedotin 1RC48 antibody 1Paclitaxel 1Gemcitabine 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-low Breast Cancer × Paclitaxel × Breast × Clear all
NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
566 enrolled
Breast

HER2-low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡